Global Gastrointestinal Drugs Market Insights, Forecast to 2029

Global Gastrointestinal Drugs Market Insights, Forecast to 2029

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Gastrointestinal Drugs estimated at US$ 40922.6 million in the year 2023, is projected to reach a revised size of US$ 53820 million by 2029, growing at a CAGR of 4.67% during the forecast period 2023-2029.

The North America market for Gastrointestinal Drugs is estimated to increase from $ 12575 million in 2023 to reach $ 16238 million by 2029, at a CAGR of 4.35% during the forecast period of 2023 through 2029.

The China market for Gastrointestinal Drugs is estimated to increase from $ 5988 million in 2023 to reach $ 8670 million by 2029, at a CAGR of 6.36% during the forecast period of 2023 through 2029.

The Europe market for Gastrointestinal Drugs is estimated to increase from $ 8712 million in 2023 to reach $ 11420 million by 2029, at a CAGR of 4.61 % during the forecast period of 2023 through 2029.

The global key manufacturers of Gastrointestinal Drugs include Takeda, Bausch Health, Abbvie, AstraZeneca, Teva, Bayer, Pfizer, Sun Pharma, etc. In 2022, the global top five players had a share approximately 40.67% in terms of revenue.

Report Includes

This report presents an overview of global market for Gastrointestinal Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Gastrointestinal Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Gastrointestinal Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastrointestinal Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Gastrointestinal Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Gastrointestinal Drugs sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including AstraZeneca, Sanofi, Bayer, Pfizer, GSK, Teva, Zeria, Perrigo, and Boehringer Ingelheim, etc.

By Company

Takeda

AstraZeneca

Bayer

Pfizer

Sun Pharma

Teva

Zeria

Perrigo

Eisai Co.

Abbvie

Jiangzhong

AOSAIKANG Pharma

Luoxin Pharma

LIVZON

Huadong Pharmaceutical

Bausch Health

Segment by Type

Prescription Gastrointestinal Drug

OTC Gastrointestinal Drug

Segment by Application

Inflammatory Bowel Disease

IBS Disease

Peptic Ulcer

GERD

Other

Segment by Region

North America

U.S.

Canada

China

Asia (excluding China)

Japan

South Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East, Africa, Latin America

Brazil

Mexico

Middle East

Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Gastrointestinal Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 3: Detailed analysis of Gastrointestinal Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (North America) by Type, by Application and by country, sales, and revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.

Chapter 8: China by Type, and by Application, sales, and revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.

Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastrointestinal Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 14: The main points and conclusions of the report.